Among the listed medications, which one is primarily used in the treatment of neovascular AMD?

In the context of neovascular age-related macular degeneration (AMD), both Brolucizumab and Aflibercept are significant treatment options. These medications are classified as anti-VEGF (vascular endothelial growth factor) therapies, which play a crucial role in managing conditions characterized by abnormal blood vessel growth in the retina, such as neovascular AMD.

Aflibercept works by acting as a decoy receptor that binds to VEGF, effectively inhibiting its activity and preventing the proliferation of abnormal blood vessels. It has been extensively studied and is approved for the treatment of neovascular AMD, providing substantial benefits in vision preservation and improvement for patients.

Brolucizumab, a newer entry in this class, also targets VEGF but features a unique formulation that allows for a lower dosing frequency compared to traditional treatments. Clinical trials have shown its efficacy in reducing the signs of neovascular AMD and its potential for enhancing treatment adherence due to less frequent injections.

Thus, recognizing that both medications are utilized in treating neovascular AMD is fundamental, as each has demonstrated effectiveness in improving patient outcomes. This makes the option that includes both treatments the most accurate choice.